December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
One-year outcomes from the phase II DREAMM-2 trial showed comparable outcomes with belantamab mafodotin in patients with R/R MM after either 3-6 or ≥ 7 prior lines of therapy.